No Data
No Data
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $51
Hold Rating on Bristol-Myers Squibb Amid Patent Expirations and Speculative Prospects of Milvexian
Express News | Bristol-Myers Squibb Co : Jefferies Raises Target Price to $51 From $49
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Market Whales and Their Recent Bets on BMY Options
RDK79 : Sorry, what’s a pdufa?